"Dear Madam, Dear Sir, 

We are very pleased with the success of our IPO. SMAIO's distinctive approach, through its global offer combining precise planning, tailor-made execution and an analytical long term patient data follow-up, has convinced many investors, both institutional and private. Pioneering in the use of Big Data^[1] to treat spinal pathologies, SMAIO offers an innovative strategy in the spine surgery market, which is growing steadily and is highly concentrated in the United States. The funds raised through the IPO, and the support of our partner NuVasive, whom I would like to thank, as well as the many shareholders who joined us on this occasion, will help us to considerably accelerate our commercial development, particularly in the US. We also intend to fully exploit the immense potential of our KEOPS database and our tailor-made surgical technologies opening the way to active robotics and the progressive automation of surgical procedures.”

Philippe ROUSSOULY
Chairman and CEO

^[1] SMAIO is developing an algorithm to restore the physiological shape of the back based on a database of over 100,000 patient records.